Halozyme Therapeutics (HALO) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.81 +1.70%
Revenue Growth %: +37.6%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +37.6%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $56.9 million versus the consensus estimate of $67.8 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $209.1 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- SharkNinja (SN) Tops Q3 EPS by 74c; Offers Guidance
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
